TCON News and Press, TRACON Pharmaceuticals Inc. From 09/18/23

SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life sci...

2023-08-14 18:50:18 ET TRACON Pharmaceuticals, Inc. (TCON) Q2 2023 Earnings Call August 14, 2023 16:30 PM ET Company Participants Charles P. Theuer - President and CEO Scott B. Brown - Chief Financial Officer Conference Call Participants Joel Beatty - Rob...

2023-08-14 16:55:45 ET Tracon press release ( NASDAQ: TCON ): Q2 GAAP EPS of -$0.20 misses by $0.17 . Revenue of $9M. Shares -0.8% . For further details see: Tracon GAAP EPS of -$0.20 misses by $0.17, revenue of $9M

SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other lif...

2023-08-13 17:35:24 ET Major earnings expected after the bell on Monday include: Suncor Energy ( SU ) Canoo ( GOEV ) Sachem Capital Corp. ( SACH ) Astra Space ( ASTR ) Ayro ( AYRO ) For further details see: Notable earnings after Monday's ...

2023-08-03 10:48:49 ET In a stock market characterized by growing unpredictability, traders are leaning on every possible resource. One such indispensable tool, whether dealing with penny stocks or more expensive shares, is the insight provided by analysts. This expertise can shed l...

SAN DIEGO, Aug. 02, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other lif...

SAN DIEGO, July 11, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life scie...

Single Agent Envafolimab ORR Exceeded Futility Rule that will be Applied at the Interim Efficacy Analysis Expected in Q3 Continuing Double-Digit Objective Response Rate (ORR) by Blinded Independent Central Review Achieved to Date in Single Agent Envafolimab Cohort without any > Grade...

SAN DIEGO, June 16, 2023 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals, Inc. (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform ...